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Abstract
Adjuvant use of safe compounds with anti-tumour properties has been proposed to improve cancer chemotherapy outcome. We aimed to
investigate the effects of fish oil emulsion (FOE) rich in n-3 PUFA with the standard chemotherapeutic agents 5-fluorouracil (5-FU), oxa-
liplatin (OX) or irinotecan (IRI) on two human colorectal adenocarcinoma cells with different genetic backgrounds. The HT-29 (Baxþ/þ)
and LS174T (Bax2/2) cells were co-treated for 24–72 h with 1mM-5-FU, 1mM-OX or 10mM-IRI and/or FOE dilution corresponding to
24mM-EPA and 20·5mM-DHA. Soyabean oil emulsion (SOE) was used as isoenergetic and isolipid control. Cell viability, apoptosis and
nuclear morphological changes were evaluated by cytotoxic colorimetric assay, flow cytometry analysis with annexin V and 40,60-diami-
dino-2-phenylindole staining, respectively. A cationic fluorescent probe was used to evaluate mitochondrial dysfunction, and protein
expression involved in mitochondrial apoptosis was determined by Western blot. In contrast to SOE, co-treatment with FOE enhanced
significantly the pro-apoptotic and cytotoxic effects of 5-FU, OX or IRI in HT-29 but not in LS174T cells (two-way ANOVA, P , 0·01).
These results were confirmed by the formation of apoptotic bodies in HT-29 cells. A significant increase in mitochondrial membrane
depolarisation was observed after the combination of 5-FU or IRI with FOE in HT-29 but not in LS174T cells (P , 0·05). Co-administration
of FOE with the standard agents, 5-FU, OX and IRI, could be a good alternative to increase the efficacy of chemotherapeutic protocols
through a Bax-dependent mitochondrial pathway.
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Colorectal cancer is the third commonly diagnosed cancer in
Western countries(1). Although complete resection of the pri-
mary tumour is sufficient in the early stages of disease, adju-
vant pre- or post-surgical chemotherapy is required in the
case of advanced disease in order to prevent local recurrence
and metastatic spreading. Chemotherapy regimens commonly
used in colorectal cancer consist of folinic acid (FOL) and
5-fluorouracil (5-FU) administration combined with oxaliplatin
(OX) (i.e. FOLFOX) or irinotecan (IRI) (i.e. FOLFIRI)(2,3).
Unfortunately, response to these chemotherapy regimens is
often partial and 85 % of patients relapse within the first
2 years after treatment(4), and they display numerous side
effects, such as myelosuppression, mucositis, dermatitis and
diarrhoea(5). Consequently, dietary intervention has recently
emerged as an innovative approach to enhance the efficacy
of conventional anti-cancer drugs, while minimising their
side effects(6). A number of antioxidant vitamins, trace
elements and phytochemicals have been identified in fruits
and vegetables as having potential benefits not only in
the prevention, but also in the treatment of cancer(7–12).
Long-chain n-3 PUFA, mainly EPA and DHA, have also
demonstrated preventive and therapeutic anti-cancer proper-
ties(13), but they differ from these nutrients by their rather
pro-oxidant mechanisms of action(14). Indeed, n-3 PUFA incor-
poration in membrane phospholipids promotes free-radical
chain reactions and subsequent interaction of lipid peroxi-
dation products with DNA. The resulting DNA adducts in
turn cause cell cycle arrest for base excision repair or apopto-
sis induction. Others and we have reported that both DHA and
EPA had potent anti-proliferative and pro-apoptotic effects in
different human colorectal adenocarcinoma cell lines, includ-
ing LS174T, CO112 and HT-29(15). In vivo, n-3 PUFA are
usually administered in the form of fish oil containing signifi-
cant amounts of the antioxidant, vitamin E. Nevertheless a fish
oil-supplemented diet was reported to suppress breast tumour
growth in mouse models by increasing intra-tumoural oxi-
dative stress and apoptosis, probably via N-SMYase or cas-
pase-8 activation(16,17). Decrease in aggressive tumour
growth was also observed in nude mice xenografted with
SW620 colorectal tumours(18). The pro-apoptotic properties
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of n-3 PUFA were furthermore assumed to act synergistically
with several anti-cancer treatments. We indeed observed that
DHA and EPA could enhance the susceptibility of colorectal
cancer cells to X-rays(19). Other in vitro studies showed that
DHA could act synergistically with anti-tumoural agents, such
as TRAIL or docetaxel, by inducing apoptosis through modu-
lation of the caspase-8 or NF-kB pathway, respectively(20,21).
Synergy was also observed in vitro between DHA and the
reference drug in colorectal cancer, i.e. 5-FU(22,23). In line
with these results, inclusion of n-3 PUFA in the diet improved
in vivo the anti-tumour efficacy and diarrhoea toxicity related
to IRI in rats bearing colorectal tumours(24). Although much
effort has been made so far to identify the underlying mechan-
isms, the interaction between n-3 PUFA and chemotherapeutic
drugs remains complex and probably involves not only an
increased oxidative stress, but also other mechanisms, such
as modulation of pro-inflammatory PG or alteration of cell
membrane fluidity and properties(25).
In the present study, we aimed to evaluate whether it was
possible to observe a synergistic effect of n-3 PUFA using
fish oil emulsion (FOE) together with the three chemothera-
peutic agents most commonly used in colorectal cancer. The
present results indicate that FOE co-administration can effec-
tively act together with 5-FU, OX and IRI to kill colorectal
cancer cells.
Methods
Cell lines and culture
The human colorectal adenocarinoma cell lines HT-29 and
LS174T were obtained from the ATCC collection. Both cell
lines were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10 % fetal calf serum, 0·1 % antibiotic cock-
tail of penicillin/streptomycin (Sigma) in a humidified atmos-
phere at 378C containing 5 % CO2.
Chemicals
The FOE (Omegavenw) and soyabean oil emulsion (SOE)
(Lipovenoesw) were obtained from Fresenius Kabi. According
to the certificate of analysis, FOE (4689 kJ/l (1120 kcal/l),
273 mosm/l, d ¼ 0·998 g/ml) contained 25 g/l glycerol, 12 g/l
(3-sn-phosphatidyl)-choline, 193 mg/l D,L-a-tocopherol and
113 g/l total lipids including 20·6 g/l EPA and 19 g/l DHA.
The SOE (8374 kJ/l (2000 kcal/l), 330mosm/l, d ¼ 0·987g/ml)
contained 25 g/l glycerol, 12 g/l (3-sn-phosphatidyl)-choline
(egg lecithin) and 213 g/l total lipids. The chemotherapeutic
agents, 5-FU, OX and IRI were kindly provided by our hospital
pharmacy.
Cell treatment
Unless otherwise specified, cells were not treated or treated
for 24–72 h with 1mM-5-FU, 1mM-OX or 10mM-IRI combined
with or without FOE dilution of 1:2850, corresponding to
24mM-EPA and 20·5mM-DHA. As control, SOE was diluted
twice as compared with FOE to serve as an isoenergetic and iso-
lipid control.
Cytotoxic assays
The cytotoxic potential of the different treatments was
determined with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay (Sigma Aldrich). Cells were seeded
at a density of 4000 cells per well in ninety-six-well plates
(Costar). After treatments of 48–72 h, 5 mg/ml of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was
incubated for 4 h at 378C with 5 % CO2, 95 % air and complete
humidity. Cells were then lysed with 200ml of dimethyl sulph-
oxide and the percentage of viable cells was calculated with
the optical density of the wells using a plate reader at a test
wavelength of 570 nm and a reference wavelength of 630 nm.
Flow cytometry analyses
Apoptosis induction was evaluated with flow cytometry ana-
lyses. At 24 h before treatment, cells were seeded at a density
of 500 000 cells per well in six-well plates. After treatment
for 24 h, cells were detached with trypsin-EDTA (Gibco) and
centrifuged at 1200 rpm for 5 min. The pellet was then
resuspended in 100ml of staining solution containing annexin-
V-fluorescein isothiocyanate and propidium iodide and 400ml
of buffer was added before flow cytometry analysis, according
to the manufacturer’s instruction (FITC Annexin V Apoptosis
Detection kit; BD Pharmingen). For experiments evaluating
loss of mitochondrial membrane depolarisation, cells were sub-
mitted to the same treatment and the tetramethyl rhodamine
methyl ester (TMRM; Invitrogen) probe was added in the culture
medium.Briefly, cellswere loadedwith 500 nM-TMRM for 15min
at 378C and red fluorescence was determined by fluorescence-
activated cell sorter analysis using FL2 setting. For every analysis,
10 000 events were recorded using Accuri C6 equipment and the
corresponding Accuri C6 software (BD Biosciences).
Fluorescence microscopy
Formation of apoptotic bodies in the nucleus was evaluated
with fluorescence microscopy after 40,60-diamidino-2-phenylin-
dole (DAPI) staining. After carrying out different treatments, the
cells were harvested with PBS and pellets (5000 cells/ml) were
re-suspended in 4 % paraformaldehyde solution for 30 min
at room temperature. A measure of 10 ml of the suspension
was mixed with 10ml of Vectashieldw Mounting Medium
(Immuno-Diffusion) with DAPI (1·5 mg/ml) and placed on a
glass slide. Cell nuclei morphology and apoptotic bodies
were visualised and scored at £ 40 in three fields of 100 cells
for each sample using an Axiocam-histo microscope (Carl
Zeiss) and its corresponding Axio Vision Software (Carl Zeiss).
Western blot analyses
Protein expressions of Bax, Bcl-2 and caspase-9 were evaluated
using Western blot analyses. At 1 d before the experiment, cells
were seeded onto 100-mm diameter tissue culture dishes con-
taining complete Dulbecco’s modified Eagle’s medium and
incubated at 378C. Cells were then washed once with ice-cold
PBS. A volume of 100ml of ice-cold NP-40 lysis buffer
(50 mM-Tris, pH 7·5, 150 mM-NaCl, 1 % Nonidet P-40, Complete;
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Protease Inhibitor Cocktail (Roche Applied Sciences)) was
added and incubated for 30 min on ice. Lysates were sedimented
at top speed for 10 min at 48C to remove cell debris and nuclei.
The protein concentration of the supernatants was determined
by the BioRad Protein assay. Equal protein amounts were
solubilised in Laemmli sample buffer and separated electro-
phoretically by SDS-PAGE and then immunotransferred onto
Odysseyw nitrocellulose membrane (LI-COR Biosciences
GmbH). For immunoblotting analysis, the membrane was
blocked in PBS containing 0·01 % Tween 20 and 5 % non-fat
milk and incubated with the primary antibody overnight at 48C
under agitation. The membrane was then washed with PBS con-
taining 0·01 % Tween 20 and incubated for 30 min with second-
ary antibodies, such as goat anti-rabbit IRDyew 680 or goat
anti-mouse IRDYedw 800CW (LI-COR Biosciences GmbH).
After washing with PBS containing 0·01 % Tween 20, all the
membranes were analysed with Odyssey software (LI-COR
Biosciences GmbH). The primary antibodies used were a
mouse anti-human Bax antibody (clone 2D2; Santa Cruz),
a rabbit anti-human Bcl-2 antibody (clone N-19; Santa Cruz),
a mouse anti-human caspase-9 antibody (Cell Signaling) or a
rabbit polyclonal anti-Hsc70 antibody as loading control
(Millipore). Ratios of protein expression between the different
treatments and the control conditions were obtained after band
quantification was normalised to the loading control Hsc70,
using ImageJ 1.45 s software (National Institutes of Health).
Results are representative of three independent experiments.
Data analysis
Every experiment was performed in triplicate samples and
repeated three times. The variables were expressed as pro-
portions or means and standard deviations, as appropriate.
Cell viability data were normally distributed according to
skewness and kurtosis. Differences in cell viability to che-
motherapy (5-FU, OX or IRI) v. chemotherapy with FOE or
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Fig. 1. Cytotoxic dose–response curves were obtained after a 72-h treatment with 5-fluorouracil (5-FU), oxaliplatin (OX) or irinotecan (IRI) in combination or not
with fish oil emulsion (FOE, ) and soyabean oil emulsion (SOE, ) in (a) HT-29 and (b) LS174T cells, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide assays. Values are means and standard deviations for three independent experiments. Statistical analysis showed a significant difference between
5-FU, OX and IRI treatment with and without FOE in HT-29, but not in LS174T cells, using a two-way ANOVA followed by a post hoc Dunnett test (P,0·01).
, Not treated.
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SOE groups as well as doses were analysed with two-way
ANOVA followed by a post hoc Dunnett test. All the statistical
analyses for the other experiments were based on the
Student’s t test. SPSS 18.0 software for Windows (SPSS, Inc.)
was used and P,0·05 was considered to be significant.
Results
Fish oil emulsion enhanced the cytotoxic effect of
5-fluorouracil, oxaliplatin and irinotecan in HT-29 cells
Cytotoxic dose–response curves were obtained after a 72-h
treatment with 5-FU, OX or IRI in combination or not with
FOE or SOE in HT-29 (Fig. 1(a)) and LS174T (Fig. 1(b))
cells, using colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assays. All three chemotherapeutic
agents inhibited cell viability in a dose-dependent manner,
OX and IRI being the most and least efficient, respectively.
As the transition between the shoulder and the slope of the
dose–response curve was about 1mM for 5-FU and OX and
10mM for IRI, these doses were chosen to set up the exper-
imental conditions for characterisation of the synergistic mech-
anisms between FOE and these drugs. When 5-FU, OX or IRI
treatment was combined with FOE dilution corresponding to
24mM-EPA and 20·5mM-DHA, the viability of HT-29 cells
was significantly reduced (P,0·01). This modulatory effect
of FOE could not be reproduced by administration of
isoenergetic and isolipid SOE (Fig. 1(a)) or by administration of
either of the lipid emulsions in the LS174T cell line (Fig. 1(b)).
Fish oil emulsion enhanced the pro-apoptotic effect of
5-fluorouracil, oxaliplatin and irinotecan in HT-29 cells
To further examine the cell death pathway induced by the
different treatment combinations, membrane phospholipid
externalisation of phosphatidylserine was evaluated using
fluorescence-activated cell sorter analysis with Annexin V/pro-
pidium iodide staining. The number of HT-29 cells in early-
stage apoptosis was significantly enhanced when 5-FU, OX
or IRI treatment was combined with FOE dilution correspond-
ing to 24mM-EPA and 20·5mM-DHA (P , 0·05). Again, the
modulatory effect of FOE could not be reproduced by SOE
(Fig. 2(a)) or by either of the lipid emulsions in the LS174T
cell line (Fig. 2(b)), except when SOE was combined with
IRI, inducing a significant increase in apoptotic HT-29 cells
(P,0·05). However, apoptosis induction remained greater
after IRI combination with FOE compared with SOE
(P,0·05). The pro-apoptotic effect of FOE combination with
5-FU, OX or IRI was confirmed by the quantification of frag-
mented and condensed nuclei in DAPI-stained HT-29 cells
(Fig. 2(c, d)). Taken together, these data confirmed the ability
of FOE to enhance the anti-tumour action of the three drugs
NT
NT
NT
5-
FU
5-FU
SO
E
SO
E-
5-
FU
FO
E-
5-
FUFO
E
SOE
FOE
SOE FOE
IR
I
OX
IRI
(c) (d)
(b)
(a)
OX
NT SOE FOENT SOE FOENT
SOE
*
**
**
**
FOENT SOE FOENT SOE FOENT
SO
EI
RI
SO
EO
X
FO
EI
RI
FO
EO
X
30
25
20
15
10
5
0
30
25
20
15
10
5
0
30
25
20
15
10
5
0
30
P
er
ce
n
ta
g
e 
o
f 
ap
o
p
to
ti
c
ce
ll 
(D
A
P
I)
25
20
15
10
5
0
30
25
20
15
10
5
0
30
25
20
15
10
5
0
35
† †
†
30
25
20
15
10
5
0
Fig. 2. Apoptosis induction was evaluated after a 24-h treatment with 1mM-5-fluorouracil (5-FU, ), 1mM-oxaliplatin (OX, ) or 10mM-irinotecan (IRI, ) in combi-
nation or not with fish oil emulsion (FOE) or soyabean oil emulsion (SOE) in (a) HT-29 and (b) LS174T cells, using fluorescence-activated cell sorter analysis with
annexin-V-fluorescein isothiocyanate and propidium iodide staining. Values are means and standard deviations for three independent experiments (**P , 0·05
FOE/chemoT v. chemoT, *P , 0·05 SOE/chemoT v. chemoT). The percentage of HT-29 apoptotic cells was also evaluated through nuclear morphological
changes, using 40,60-diamidino-2-phenylindole staining. (c) White arrows indicate nuclei condensation and apoptotic body formation. (d) Statistical analysis showed
a significant difference between samples with or without FOE in the context of 5-FU, OX or IRI treatment †(P , 0·05). NT, Not treated. (A colour version of this
figure can be found online at http://www.journals.cambridge.org/bjn)
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commonly used in colorectal cancer treatment. However, the
efficiency of such a treatment combination appeared to
depend on the genetic background of the target cells.
Fish oil emulsion induced a loss of mitochondrial
membrane potential (Dwm) in HT-29 cells
Mitochondria are important players in the cell death pathway,
which involves activation of the pro-apoptotic Bcl-2 family
member, Bax, leading to apoptosis. To assess whether mito-
chondrial membrane permeation by Bax was involved in
the differential sensitivity of HT29 (Baxþ/þ) and LS174T
(Bax2/2) cell lines, a TMRM fluorescent probe was used after
the different treatment combinations. Results confirmed that
the number of depolarised cells was significantly higher in
HT-29 cells after FOE combination with 5-FU and IRI
(P,0·05), whereas there was no significant change in LS174T
cells (Fig. 3(a, b)).
Involvement of mitochondria-related protein expression in
the cell sensitivity to the different treatment combinations
was further assessed by Western blot analysis. Bax protein
expression was detected in HT-29 but not in LS174T cells.
However, there was no significant change in Bax expression
following FOE combination with 5-FU, OX or IRI (Fig. 4). Pro-
tein expression of the anti-apoptotic Bcl-2 appeared to be
slightly down-regulated after 5-FU or OX, but not after IRI
treatment in both cell lines. However, it was not possible to
observe any modulating effect of FOE or SOE, apart from a
decrease in Bcl-2 expression when FOE was combined with
IRI treatment in HT-29 cells, contrasting with the increase in
Bcl-2 expression observed when FOE was combined with
OX treatment in LS174T cells (Fig. 4). Caspase-9 activation
was observed in HT-29 cells through a diminution of
caspase-9 proform after FOE, 5-FU, OX or IRI treatment.
Combination of these drugs with FOE seemed to further
reduce the amount of caspase-9 proform, whereas there was
no modulatory effect of either FOE or SOE in LS174T cells
(Fig. 4). All together, these data suggest that the Bax status
could be involved in a selective mechanism responsible for
FOE-induced apoptosis through mitochondrial pathway.
Discussion
The present study investigates the therapeutic potential of a
combination of n-3 PUFA, in the form of FOE, with three che-
motherapeutic agents commonly used in colorectal cancer
management. The present results showed that FOE could act
together with these agents to inhibit colorectal cancer cell
growth. The fact that an anti-cancer action of FOE was
observed in the presence of low doses of 5-FU, OX and IRI
is of particular interest as part of a strategy designed to
reduce chemotherapy-related side effects.
Although the anti-tumour effect of n-3 PUFA is well
known(14), it was not certain to get similar results with the
administration of FOE containing significant amounts of the
antioxidant vitamin E. Indeed, it has been shown that n-3
PUFA act at least in part by increasing intra-tumoural oxidative
stress(26). Therefore, the presence of vitamin E in FOE could
annihilate the cytotoxic effect of n-3 PUFA by blocking their
peroxidation cascade in cell membranes. We previously
observed that a-tocopherol could effectively inhibit the cyto-
toxic and pro-apoptotic effects of pure n-3 PUFA on different
colorectal adenocarcinoma cell lines, including HT-29 and
LS174T(19). Although certain isoforms of vitamin E, such as
g-tocopherol, were shown to have a similar pro-apoptotic
effect than n-3 PUFA(27), we and others demonstrated that
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Fig. 3. Change in mitochondrial potential membrane (Dwm) was evaluated after a 24-h treatment with 1mM-5-fluorouracil (5-FU), 1mM-oxaliplatin (OX) or 10mM-iri-
notecan (IRI) in combination or not with fish oil emulsion (FOE) or soyabean oil emulsion (SOE) in (a) HT-29 and (b) LS174T cells, using tetramethyl rhodamine
methyl ester flow cytometry analysis. Statistical analysis showed a significant difference between 5-FU and IRI treatment without and with FOE in HT-29, but not
in LS174T cells (*P,0·05). NT, Not treated.
V. Granci et al.1192
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S000711451200308X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:17:44, subject to the Cambridge Core terms of use, available at
a-tocopherol, the only isoform present in the FOE used in the
present study, had no intrinsic effect on different colorectal
cancer cells(19,27). Consequently, we assumed here that the
increased apoptosis, which was observed after combining
FOE with the chemotherapeutic drugs, was due to the presence
of long-chain n-3 PUFA, such as DHA or EPA, rather than to the
presence of a-tocopherol. Results of fluorescence-activated cell
sorter analysis with annexin V were confirmed by DAPI staining
showing the formation of apoptotic bodies in cells co-treated
with FOE and 5-FU, OX or IRI. However, the anti-cancer
effect of such a combination was observed only in HT-29 but
not in LS174T cells. The mode of action of the three standard
chemotherapeutic drugs used in colorectal cancer has been
well established for decades, causing cell death. Theoretically,
all of these drugs can exert cytotoxic action by directly targeting
DNA synthesis. However, the lethal effect caused by addition of
FOE could differ from one cell type to another. As characterised
by Violette et al.(28), both cell lines differ by their genetic back-
ground, HT-29 being p532/2 , Baxþ/þand LS174T being
p53þ/þ , Bax2/2 .
The main cytotoxic effect of the uracil analogue, 5-FU, is
mediated by its conversion into an active metabolite after
cancer cell uptake. This transformed active compound inter-
feres with DNA synthesis and activates the pathway involving
apoptosis induction. Recently, Nehls et al.(29) described that
mutated p53 and wild-type bax status could improve dis-
ease-free survival in 5-FU-treated patients. This is consistent
with our in vitro observation showing greater sensitivity of
HT-29 cells to 5-FU and other chemotherapeutic drugs com-
pared with LS174T cells. The IRI in association with topoi-
somerase-1 and DNA forms a complex that causes DNA
double-stranded breaks, and consequently leads to cell cycle
arrest, DNA misrepair and apoptosis. In particular, the pre-
sence of p53 expression has been suggested to be essential
to induce IRI cell death in colorectal adenocarcinoma cells
presenting a Bax-deficient pathway(30). Therefore, it was sur-
prising that our results did not show a greater sensitivity of
LS174T cells to IRI chemotherapy alone or in combination
with FOE, compared with HT-29 cells.
The OX is a nuclear DNA-damage agent that requires the
Bax/Bak pathway to induce apoptosis in colorectal cancer
cells(31). This is consistent with our in vitro flow cytometry
assays which showed a particular sensitivity of HT-29 cells
to OX, compared with LS174T cells.
Taken together, these observations suggest that FOE/che-
motherapy combination implies a complex mechanism,
which requires deeper investigation in the role of the Bax
intrinsic pathway.
Mitochondria play a central role in apoptosis and can be
qualified as a ‘point of no return’ in the apoptotic pathway
through the mitochondrial outer membrane(32). The pro-apop-
totic Bcl-2 family member, Bax, is usually located in the cyto-
sol and translocates to the outer mitochondrial membrane to
initiate events such as release of cytochrome c and other
pro-apoptotic factors in the cytosol. Caspase-9 is then acti-
vated, leading to cell death.
In order to determine if the Bax pathway could play a role
in colorectal cancer cell sensitisation by FOE to chemothera-
peutic drugs, we analysed the mitochondrial membrane
potential change using flow cytometry with the cationic fluor-
ochrome TMRM. We showed that the percentage of HT-29
depolarised cells was correlated with the quantification of
apoptotic cells under FOE treatment, whereas the level was
negligible in LS174T cells. The most important effect was
caused by IRI and 5-FU. In light of their mode of action
discussed above, these results highlight the importance of
Bax expression status in colorectal cancer cell treatment.
The present data are consistent with previous publications
No drug
(a) (b)
0 SOE
1·0 1·01·1 0·8 0·8 0·6 0·6 0·7 0·7 0·7 0·6 0·7 1·2 0·8 0·60·7 0·6 0·6 0·5 0·5 0·8 0·9 0·7
0·90·90·90·90·9 0·90·70·80·81·01·01·0
1·0 1·0 1·0 1·0 1·1 1·1 1·1 0·7 0·7 0·70·6 0·60·80·50·50·51·1 0·90·9 0·80·80·80·70·7
0·4
FOE 0 SOE FOE 0 SOE FOE 0 SOE FOE 0 SOE FOE 0 SOE FOE 0 SOE FOE 0 SOE FOE
0 SOE FOE0 SOE FOE0 SOE FOE0 SOE FOE0 SOE FOE0 SOE FOE0 SOE FOE0 SOE FOE
5-FU OX IRI
No drug 5-FU OX IRI
5-FU OX IRINo drug
5-FU OX IRINo drug
Caspase-9
proform
Bax Bax
Caspase-9
proform
Hsc70
Hsc70Hsc70
Ratio
RatioRatio
Ratio
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Bcl-2Bcl-2
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Fig. 4. Bcl-2, Bax and pro-caspase-9 protein levels were evaluated after a 24-h treatment with 1mM-5-fluorouracil (5-FU), 1mM-oxaliplatin (OX) or 10mM-irinotecan
(IRI) in combination or not with fish oil emulsion (FOE) or soyabean oil emulsion (SOE) in (a) HT-29 and (b) LS174T cells, using Western blot analyses. Ratios of
protein expression between treated and untreated cells were obtained after band quantification normalised to the loading control, Hsc70. Results are representa-
tive of three independent experiments.
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reporting the link between DHA treatment and the per-
meability transition pore of the mitochondria favouring apop-
tosis induction(33). Unlike Calviello’s study(22), we did not
observe down-regulation of Bcl-2 expression after the combi-
nation of FOE either with 5-FU or with the other two drugs,
except for IRI in HT-29 cells. This could be mainly explained
by the use of pure DHA (10mM) in the aforementioned study
instead of FOE. Modulation of caspase-9 expression was
observed only in HT-29 and not in LS174T cells, especially
with a combination of FOE with 5-FU or IRI treatment. It
means that sensitisation to chemotherapy by FOE may not
be solely due to an apoptosome-dependent pathway.
The present findings suggest that addition of FOE to three
frequently used chemotherapeutic agents may change the
mechanistic response depending on the genetic background
of cancer cells. The FOE could amplify the anti-tumoural
effect of the three drugs through a Bax-related intrinsic mito-
chondrial pathway for a stronger apoptosis induction (Fig. 5).
Clinical studies in human subjects are concordant with our
observations demonstrating the helpful benefits of n-3 PUFA
in treatment of several cancer types such as non-small-cell
lung cancer or breast cancer(34,35).
In summary, combination of FOE with low doses of the
three commonly used chemotherapeutic agents, 5-FU, OX or
IRI, could display an anti-tumour action through a Bax-depen-
dent mitochondrial pathway. Co-administration of FOE with
chemotherapy could be a good strategy to increase the che-
motherapeutic efficacy of routine protocols (i.e. FOLFOX
and FOLFIRI) in colorectal cancer treatment.
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